ARCA Biopharma Inc (ABIO) USD0.001
$0.04
(0.78%)
- Add to watchlist
- This stock can be held in a
$0.04
(0.78%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA,
SIPP or
Fund and Share Account
$0.04
(0.78%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA,
SIPP or
Fund and Share Account
Business summary
ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.
Contact details
Important dates
General stock information
- Short code:
- ABIO
- ISIN:
- US00211Y5069
- Market cap:
- $8.23 million
- Shares in issue:
- 1.59 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- NASDAQ Comb. Composite
Key personnel
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA,
SIPP or
Fund and Share Account
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.